Cara Therapeutics Stock News

Prudential Financial Inc. purchased a new position in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 46,650 shares of the biopharmaceutical companys stock, valued at approximately $666,000. Other large investors also recently bought and sold shares of the []

Equities research analysts expect Cara Therapeutics, Inc. (NASDAQ:CARA) to post earnings of ($0.50) per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Cara Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.60) and the highest estimate coming in at ($0.42). Cara Therapeutics posted earnings of […]

Cara Therapeutics Inc. (NASDAQ:CARA) shares, rose in value on Wednesday, 11/24/21, with the stock price down by -0.74% to the previous days close as strong demand from buyers drove the stock to $13.34. Actively observing the price movement in the last trading, the stock closed the session at $13.44, falling within a range of $13.06 Thinking About Buying Cara Therapeutics Inc. Stock? Heres What You Need To Know. Read More »

Charles Schwab Investment Management Inc. boosted its holdings in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) by 3.5% during the second quarter, Holdings Channel reports. The institutional investor owned 356,224 shares of the biopharmaceutical companys stock after acquiring an additional 12,078 shares during the quarter. Charles Schwab Investment Management Inc.s holdings in Cara Therapeutics were worth []

Charles Schwab Investment Management Inc. boosted its holdings in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) by 3.5% during the second quarter, Holdings Channel reports. The institutional investor owned 356,224 shares of the biopharmaceutical companys stock after acquiring an additional 12,078 shares during the quarter. Charles Schwab Investment Management Inc.s holdings in Cara Therapeutics were worth []

Cara Therapeutics Inc. (NASDAQ:CARA)s traded shares stood at 0.65 million during the last session, with the companys beta value hitting 1.05. At the close of trading, the stocks price was $14.18, to imply a decrease of -1.80% or -$0.26 in intraday trading. The CARA shares 52-week high remains $29.65, putting it -109.1% down since that Cara Therapeutics Inc. (NASDAQ: CARA) Has Fallen -109.1% From Its Highs, What Comes Next? Read More »

Price T Rowe Associates Inc. MD reduced its holdings in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) by 54.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,047,488 shares of the biopharmaceutical companys stock after selling 1,251,811 shares during the []

STAMFORD, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Christopher Posner, President and Chief Executive Officer, Thomas Reilly, Chief Financial Officer, and Joana Goncalves, M.D., Chief Medical Officer, will participate in a fireside chat at the Piper Sandler 33 rd Annual Virtual Healthcare Conference. The fireside chat will be available beginning Monday, November 22, 2021 at 10:00 a.m. ET.

STAMFORD, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical e

TheStreet upgraded shares of Cara Therapeutics (NASDAQ:CARA) from a d+ rating to a c rating in a research report sent to investors on Friday morning, TheStreetRatingsTable reports. Other analysts have also recently issued reports about the stock. Zacks Investment Research raised shares of Cara Therapeutics from a sell rating to a hold rating in a []

Nuveen Asset Management LLC trimmed its holdings in Cara Therapeutics, Inc. (NASDAQ:CARA) by 2.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 599,653 shares of the biopharmaceutical companys stock after selling 15,764 shares during the period. Nuveen Asset Management LLCs holdings in Cara []

Zacks Investment Research upgraded shares of Cara Therapeutics (NASDAQ:CARA) from a sell rating to a hold rating in a research note issued to investors on Thursday morning, Zacks.com reports. According to Zacks, Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara []

Analysts expect that Cara Therapeutics, Inc. (NASDAQ:CARA) will post earnings per share (EPS) of ($0.50) for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Cara Therapeutics earnings. The lowest EPS estimate is ($0.60) and the highest is ($0.42). Cara Therapeutics posted earnings per share of $1.59 during the same quarter []

STAMFORD, Conn., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alle

Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q3 2021 Results - Earnings Call Transcript